Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
Lexicon Pharmaceuticals (NASDAQ: LXRX) is set for a May 2023 PDUFA date for their NDA for sotagliflozin in heart failure treatment, confirmed during a recent FDA meeting. The company highlighted positive outcomes from their SOLOIST-WHF trial, showing a 50% reduction in readmission rates for heart failure post-discharge. For LX9211, the Phase 2 studies in diabetic peripheral neuropathic pain and postherpetic neuralgia showed promising results, though the latter's primary endpoint wasn't statistically significant. Financially, Q4 2022 recorded a net loss of $30.5 million but has $138.4 million in cash, a notable increase from $86.7 million in Q4 2021.
- Sotagliflozin NDA on track for May 2023 PDUFA date.
- SOLOIST-WHF trial shows 50% relative risk reduction in heart failure readmissions.
- Financial stability with $138.4 million in cash and investments as of December 31, 2022.
- Fourth quarter net loss of $30.5 million, higher than prior year.
- Increased SG&A expenses due to preparations for sotagliflozin's market launch.
- Phase 2 study of LX9211 in postherpetic neuralgia did not meet primary endpoint for significance.
NDA for Sotagliflozin on Track for May 2023 PDUFA date following Late-Cycle Review Meeting
LX9211 Demonstrates Consistent Results in Full Data from RELIEF-DPN-1 in Diabetic Peripheral Neuropathic Pain and Top-Line Data from RELIEF-PHN-1 in Post-Herpetic Neuralgia
Conference Call and Webcast at 5:00 pm Eastern Time
THE WOODLANDS, Texas, March 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2022 and provided an update on key corporate milestones.
“We are on track for the PDUFA action date in May of this year for our NDA for sotagliflozin for the treatment of heart failure, as confirmed during this week’s FDA late-cycle review meeting,” said Lonnel Coats, Lexicon’s chief executive officer. “We believe the uniqueness of our data from the SOLOIST-WHF trial provides a point of clinical differentiation and provides a strong opportunity to launch into a growing market with recently adopted medical treatment guidelines recommending the use of SGLT inhibitors as a key pillar of heart failure treatment.”
“We continue to advance the science across our portfolio with the upcoming presentation of sotagliflozin-related analyses at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology in New Orleans, Louisiana, including a featured presentation on the time to clinical benefit of sotagliflozin in people with worsening heart failure. In parallel, we are equally excited about the clinical progress of our AAK1-inhibitor, LX9211. We plan to advance LX9211 into late-stage development in neuropathic pain, supported by data from Phase 2 proof-of-concept studies in diabetic peripheral neuropathic pain (DPN) and postherpetic neuralgia (PHN), both completed in 2022.”
Fourth Quarter Highlights
Sotagliflozin
- On November 6, a new analysis of results from the SOLOIST-WHF Phase 3 outcomes study of sotagliflozin was presented at the American Heart Association Scientific Sessions 2022 in Chicago, Illinois. The oral presentation was titled “The effect of the dual SGLT1 and 2 inhibitor sotagliflozin on cardiovascular mortality and hospital readmission rates for heart failure at 30- and 90-days post discharge in patients with type 2 diabetes hospitalized for worsening heart failure in the SOLOIST-WHF trial” and showed that treatment with sotagliflozin resulted in a significant relative risk reduction versus placebo of approximately
50% for readmission for non-fatal heart failure events and for the composite of cardiovascular death and readmission for heart failure at both 30 and 90 days following hospital discharge. - A poster was presented at the American Society of Nephrology Kidney Week 2022 annual scientific meeting in Orlando, Florida on November 5. The poster was titled “Effect of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease” and described the results of a post hoc analysis of clinical data from the SCORED trial that showed sotagliflozin significantly reduced urine albumin-to-creatinine ratio (UACR) and had favorable effects on albuminuria progression and regression from a higher UACR category.
LX9211
- An oral presentation, titled “A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN-1),” was given at the 16th Annual Pain Therapeutics Summit in Washington, D.C. on November 14. The presentation of full data from the entire 11-week evaluation period of the study, which included a 5-week placebo run-off period following the initial 6-week treatment period, showed consistent and statistically significant treatment-period benefits in measures of particular importance in diabetic peripheral neuropathic pain for both dose arms compared to placebo, such as reductions in burning pain (p<0.001 and p=0.017, respectively) and interference of pain on sleep (p=0.005 and p=0.002, respectively).
- On December 21, we announced topline results of our RELIEF-PHN-1 Phase 2 proof-of-concept study of LX9211 in postherpetic neuralgia. LX9211 achieved a reduction in average daily pain score (ADPS) of 2.42 points from baseline at week 6 compared to a reduction of 1.62 points in the placebo arm, with a placebo adjusted difference of 0.80 points (p=0.12). Although these results did not reach statistical significance on the primary endpoint of the study, overall study results demonstrated clear evidence of effect. Separation of LX9211 from placebo on ADPS was seen at week 1 and maintained consistently thereafter, with an average placebo-adjusted reduction over the 6-week dosing period of 0.80 points (p=0.03).
Fourth Quarter 2022 Financial Highlights
Unless otherwise stated, all comparisons are for the fourth quarter and full year of 2022 compared to the fourth quarter and full year of 2021.
Research and Development (R&D) Expenses: Research and development expenses for the fourth quarter of 2022 decreased to
Selling, General and Administrative (SG&A) Expenses: Selling, general and administrative expenses for the fourth quarter of 2022 increased to
Net Loss: Net loss for the fourth quarter of 2022 was
Cash and Investments: As of December 31, 2022, Lexicon had
Conference Call and Webcast Information
Lexicon management will hold a live conference call and webcast today at 5:00 pm ET / 4:00 pm CT to review its financial and operating results and to provide a general business update. The dial-in number for the conference call is 888-317-6003 and the conference ID for all callers is 8206864. The live webcast and replay may be accessed by visiting Lexicon’s website at www.lexpharma.com/events. An archived version of the webcast will be available on the website for 14 days.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin, LX9211 and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, successfully commercialize any products for which it obtains regulatory approval, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Lexicon Pharmaceuticals, Inc.
Selected Financial Data
| Consolidated Statements of Operations Data | Three Months Ended December 31, | Years Ended December 31, | |||||||||||||
| (In thousands, except per share data) | 2022 | 2021 | 2022 | 2021 | |||||||||||
| (Unaudited) | (Unaudited) | ||||||||||||||
| Revenues: | |||||||||||||||
| Royalties and other revenue | $ | 28 | $ | 14 | $ | 139 | $ | 298 | |||||||
| Operating expenses: | |||||||||||||||
| Research and development, including stock-based compensation of | 13,977 | 16,498 | 52,816 | 55,046 | |||||||||||
| Selling, general and administrative, including stock-based compensation of | 16,329 | 8,846 | 48,083 | 32,342 | |||||||||||
| Total operating expenses | 30,306 | 25,344 | 100,899 | 87,388 | |||||||||||
| Loss from operations | (30,278 | ) | (25,330 | ) | (100,760 | ) | (87,090 | ) | |||||||
| Interest expense | (1,103 | ) | (295 | ) | (2,780 | ) | (802 | ) | |||||||
| Interest and other income, net | 887 | 14 | 1,596 | 134 | |||||||||||
| Net loss | $ | (30,494 | ) | $ | (25,611 | ) | $ | (101,944 | ) | $ | (87,758 | ) | |||
| Net loss per common share, basic and diluted | $ | (0.16 | ) | $ | (0.17 | ) | $ | (0.62 | ) | $ | (0.60 | ) | |||
| Shares used in computing net loss per | |||||||||||||||
| common share, basic and diluted | 188,726 | 148,897 | 165,733 | 145,652 | |||||||||||
| As of | As of | ||||||||||||||
| Consolidated Balance Sheet Data | December 31, 2022 | December 31, 2021 | |||||||||||||
| (In thousands) | |||||||||||||||
| Cash and investments | $ | 138,357 | $ | 86,743 | |||||||||||
| Property and equipment, net | 2,071 | 1,176 | |||||||||||||
| Goodwill | 44,543 | 44,543 | |||||||||||||
| Total assets | 194,299 | 136,909 | |||||||||||||
| Long-term debt, net of issuance costs | 48,579 | - | |||||||||||||
| Accumulated deficit | (1,589,720 | ) | (1,487,776 | ) | |||||||||||
| Total stockholders' equity | 117,124 | 113,595 | |||||||||||||
For Investor Inquiries:
Carrie Siragusa
Lexicon Pharmaceuticals, Inc.
csiragusa@lexpharma.com
For Media Inquiries:
Alina Kolomeyer
Lexicon Pharmaceuticals, Inc.
akolomeyer@lexpharma.com
FAQ
What is the PDUFA date for Lexicon's sotagliflozin NDA?
What were Lexicon's financial results for the fourth quarter of 2022?
What did the SOLOIST-WHF trial reveal about sotagliflozin?
How much cash does Lexicon have as of December 31, 2022?
What were the results of the LX9211 Phase 2 study?
